E-Cigarettes Spark Evolution Of FDA’s Nicotine-Containing Medical Product Regulation
This article was originally published in The Tan Sheet
Executive Summary
FDA’s tobacco, drug and medical device centers are discussing “some sort of jurisdictional policy” to “determine how to evolve the regulation of therapeutic nicotine products,” including OTC drugs, says tobacco program head Mitch Zeller.
You may also be interested in...
Emotional Backdrop Smolders As FDA Reviews Smoking Cessation Category
FDA asks for comments including evidence needed to show safety and efficacy for novel nicotine replacement therapies, but speakers at recent hearing highlight the public's psychological toll from tobacco-related deaths and the emotional connection smokers have with tobacco and nicotine.
Emotional Backdrop Smolders As FDA Reviews Smoking Cessation Category
FDA asks for comments including evidence needed to show safety and efficacy for novel nicotine replacement therapies, but speakers at recent hearing highlight the public's psychological toll from tobacco-related deaths and the emotional connection smokers have with tobacco and nicotine.
FDA's Nicotine Replacement Standards Review Could Open Door For E-Cigarettes
Latest steps by US FDA targeting tobacco-related health problems are a Nicotine Steering Committee, headed by Commissioner Gottlieb, and a public docket, including a meeting in January, for suggestions on how novel products could be evaluated as safe and effective NRTs.